On top of this, just like ZD55′s [8]and BioVex's [25] products, the liver cancer-targeted adenoviral vector GD55 can also be armed with a panel of anti-cancer genes which would have the potential for treating HCC, such as GM-CSF that enhance the body's immune response against tumors, TRAIL or IL-24 for tumor inhibition and apoptosis, endostatin for anti-angiogensis, and antitumoral microRNA, and prodrug activating enzyme et al. We expected that GD55 carrying anti-cancer genes will obtain the synergy anticancer capacity for further liver cancer therapy. This evidence concerns the gene COL18A1 and liver cancer.